According to TNM staging, middle to late stage of lung cancer refers to stage II to IV of lung cancer in clinic, and according to the Primary Lung Cancer Diagnostic and Treatment Guidelines, the five-year survival rate of stage II to IV of non-small-cell lung cancer in China is 55%, 20% and 5%, and that of small-cell lung cancer is 25%, 8% and 3%, respectively.
Lung cancer is a malignant tumor originating in the lungs, which can be divided into two different types: non-small cell lung cancer and small cell lung cancer, and the prognosis of patients after treatment is mainly determined by their clinicopathological characteristics, which is largely related to the clinicopathological stage.
According to relevant guidelines, based on comprehensive analysis, the five-year survival rate of non-small cell cancer patients in China is about 55% for Stage II, 20% for Stage III and 5% for Stage IV, while the five-year survival rate of small cell cancer patients is relatively lower, with 25% for Stage II, 8% for Stage III and 3% for Stage IV.
Regardless of the individual’s condition, lung cancer patients should follow the doctor’s instructions for regular review after treatment. And healthy people should pay attention to regular medical checkups and intervene in time when they find abnormal lesions in their bodies.